Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prevention and treatment of gastrointestinal infection in mammals

A technology for mammals and gastrointestinal diseases, which can be used in drug combinations, medical raw materials derived from bacteria, medical preparations containing active ingredients, etc., and can solve problems such as animal harm.

Inactive Publication Date: 2013-09-25
CHR HANSEN AS
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since bacteria of the Dietzia genus can be harmful to animals, their use as acceptable probiotics is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention and treatment of gastrointestinal infection in mammals
  • Prevention and treatment of gastrointestinal infection in mammals
  • Prevention and treatment of gastrointestinal infection in mammals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0022] Higher doses of lactic acid producing bacteria are known to reduce the number of pathogens such as E. coli O157:H7 or Salmonella in cattle. Reducing pathogenic bacteria in cattle can in turn enhance the food safety of meat or milk produced from such cattle. In a preferred embodiment, the dose of lactic acid producing bacteria may be increased to 5 x 10 per mammal per day later in the animal's life, for example about 40 days before said animal is slaughtered. 8 up to 5×10 9 between CFUs. In another embodiment, the at least one probiotic suitable for use in the method of the invention may include Lactobacillus strain NP51 and Propionibacterium strain PF24.

[0023] Brief description of the drawings

[0024] figure 1 Mouse body weights measured at 15-day intervals from day 1 to day 180 are shown.

[0025] figure 2 MAP load in the liver of mice treated with VM (live MAP), VM+HNP (heat-inactivated NP51 ) or VM+VNP (live NP51 ) at day 135 is shown.

[0026] image 3 MA...

Embodiment 1

[0047] Example 1. Prevention of Mycobacterium avium subsp. paratuberculosis (MAP) infection in mice by oral administration of Lactobacillus acidophilus NP51

[0048] Three hundred and seventy (370) Balb / c mice, 185 females and 185 males, were maintained in standard mouse cages with raised wire floors in a pathogen-free environment. From 6 weeks of age, these mice were fed 3-5 grams of sterile chow containing different forms of probiotic NP51 per day until the end of the study, where the dose of probiotic NP51 was about 1x10 per mouse per day. 6 CFU. The NP51 strain was provided by Nutrition Physiology Company LLC.

[0049] Mice were placed on a diet containing the NP51 probiotic for 45 days (day 1 to day 45). On day 45, by intraperitoneal injection with 1 × 10 8 CFU heat-inactivated or live MAP challenged mice. Mice were randomized into 10 treatment groups in a factorial design, which included, for example, mice fed with heat-inactivated or live NP51 and mice challenged wi...

Embodiment 2

[0061] Example 2. NP51 Dosage Study of Balb / c Mice

[0062] To assess the health effects of long-term probiotic supplementation to animals, six-week-old Balb / c mice were fed different concentrations of probiotics over 45 days. The effects of probiotics on the histopathology of GI tissues and the gut microbiota were compared with negative controls (no probiotics fed). The health of these mice was assessed by histopathological analysis, including the following tissues: gastrointestinal tissue (esophagus, small and large intestine and stomach), liver and spleen. For the effect on the diversity of the microbiota, bacterial concentrations in intestinal tissue and fecal pellets were also analyzed.

[0063] During 45 days, 80 mice (10 mice per treatment group) were fed fresh sterile chow with either no probiotics or the inert filler maltodextrin or a concentration of 1×10 4 、10 5 or 10 6 CFU / g of mouse chow of live probiotic (NP51) or the same concentration of heat-inactivated pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods are disclosed for the prevention and / or treatment of certain gastrointestinal (GI) diseases, such as Johne's Diseases (JD) in animals and Crohn's Disease (CD) in human. Administration of certain probiotic bacteria, such as lactic acid producing bacteria, to animals helps inhibit GI infection by Mycobacterium avium subsp. paratuberculosis (MAP). MAP is the primary pathogenic agent suspected of causing various inflammatory bowel diseases in cattle or humans.

Description

[0001] Related Applications Cited [0002] This application claims priority to US Patent Application No. 61 / 327,368, filed April 23, 2010, the entire contents of which are incorporated herein by reference. field of invention [0003] The present invention relates to the use of probiotics to prevent and / or treat certain gastrointestinal (GI) diseases, such as Johne's Disease (JD) in animals and Crohn's Disease (CD) in humans. In particular, the present invention relates to the inhibition of GI infection caused by Mycobacterium avium subsp. paratuberculosis (MAP). Background of the invention [0004] One of the most common bovine inflammatory bowel diseases (IBDs), John's disease (JD), shares many clinical manifestations with the human inflammatory bowel disease Crohn's disease (CD). John's disease is a contagious, chronic, and often fatal infection that primarily affects the small intestine of ruminants. John's disease is caused by Mycobacterium avium subspecies paratubercu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P1/04A61P1/00
CPCA61K35/74A61P1/00A61P1/04A61K35/747
Inventor 道格拉斯·R·乌艾尔
Owner CHR HANSEN AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com